Last reviewed · How we verify

Arotinolol Hydrochloride — Competitive Intelligence Brief

Arotinolol Hydrochloride (Arotinolol Hydrochloride) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-beta blocker. Area: Cardiovascular.

marketed Alpha-beta blocker Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Arotinolol Hydrochloride (Arotinolol Hydrochloride) — Sumitomo Pharma (Suzhou) Co., Ltd.. Arotinolol hydrochloride is a non-selective beta-adrenergic receptor antagonist with alpha-1 blocking activity that reduces heart rate and blood pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Arotinolol Hydrochloride TARGET Arotinolol Hydrochloride Sumitomo Pharma (Suzhou) Co., Ltd. marketed Alpha-beta blocker Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor
Carvedilol CR Carvedilol CR University of Florida marketed Non-selective beta-blocker with alpha-1 blocking activity Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor
Carvedilol alone Carvedilol alone Taipei Veterans General Hospital, Taiwan marketed Beta-blocker with alpha-1 antagonist activity Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor
Comparator: carvedilol Comparator: carvedilol Organon and Co marketed Beta-blocker with alpha-1 antagonist activity Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor
Beta Blockers Carvedilol Phosphate Beta Blockers Carvedilol Phosphate Seoul National University Hospital marketed Beta blocker (non-selective, with alpha-1 blocking activity) Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor
CarVeDilol-SR (Slow Release) CarVeDilol-SR (Slow Release) Seoul National University Bundang Hospital marketed Beta-blocker with alpha-1 blocking activity Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor
Carvedilol IR 25mg, QD Carvedilol IR 25mg, QD Chong Kun Dang Pharmaceutical phase 3 Beta-blocker with alpha-1 antagonist activity Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-beta blocker class)

  1. Sumitomo Pharma (Suzhou) Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Arotinolol Hydrochloride — Competitive Intelligence Brief. https://druglandscape.com/ci/arotinolol-hydrochloride. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: